Innate Pharma
Clinical-stage biotech developing NK cell-engaging antibodies for cancer immunotherapy.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Innate Pharma SA is a global, clinical-stage biotechnology company specializing in immuno-oncology. Founded in 1999 by pioneers in innate immunity, the company is dedicated to developing innovative therapeutic antibodies that harness the body's immune system to fight cancer. Its pipeline features proprietary and partnered drug candidates derived from its expertise in Natural Killer (NK) cell biology. A key proprietary technology is the ANKET® (Antibody-based NK cell Engager Therapeutics) platform, which generates multispecific antibodies to engage NK cells against tumors. The company focuses on addressing high unmet medical needs for cancer patients through its novel immunotherapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-22 13:41 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 487.1 KB | ||
| 2025-09-02 07:00 |
Declaration of Voting Results & Voting Rights Announcements
Total number of voting rights and capital / Information on the total number of …
|
English | 157.7 KB | ||
| 2025-09-02 07:00 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 135.3 KB | ||
| 2025-07-11 11:24 |
Major Shareholding Notification
Franchissements de seuils
|
French | 116.0 KB | ||
| 2025-06-17 07:00 |
Investor Presentation
Informations privilégiées / Autres communiqués
|
French | 165.5 KB | ||
| 2025-06-17 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 204.3 KB | ||
| 2025-06-13 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 179.5 KB | ||
| 2025-06-13 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 273.5 KB | ||
| 2025-05-27 07:00 |
Report Publication Announcement
Inside Information / Other news releases
|
English | 210.2 KB | ||
| 2025-05-27 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 173.9 KB | ||
| 2025-05-23 07:00 |
Post-Annual General Meeting Information
Inside Information / Other news releases
|
English | 232.8 KB | ||
| 2025-05-23 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 230.4 KB | ||
| 2025-05-23 07:00 |
Earnings Release
Informations privilégiées / Autres communiqués
|
French | 188.7 KB | ||
| 2025-05-19 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 181.7 KB | ||
| 2025-05-19 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 148.3 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
